Clinical Studies
Articles tagged with Clinical Studies
Screening modestly reduces prostate cancer deaths
Viagra could hold key to halting Peyronie’s disease
A simple X-ray measure linked to survival in lung cancer surgery patients
Antibody spurs nerve fiber regrowth following spinal cord injury
A novel antibody, NG101, accelerates the regeneration of damaged spinal cord tissue by neutralizing a protein that blocks nerve fiber growth. This therapy enables new nerve fibers to form functional connections, allowing patients to become more independent and potentially recover arm and hand function.
Rethinking bladder cancer surveillance: Can fewer procedures be just as effective?
Amplified Sciences enrolls patients in PanAMP real-world, multicenter clinical utility study
New study finds low-dose eye drops successful in managing adult myopia for 24 hours
A new study published in Eye and Vision finds that one drop of low-dose atropine can produce daylong effects in managing myopia. The researchers found that the drop showed clear changes in pupil size and focusing ability, but no short-term structural effects on the eye.
Trial now enrolling seeks to answer key question: Does adding chemotherapy to hormone therapy improve survival for metastatic prostate cancer?
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
Chinese Medical Journal article review highlights a growing global consensus on acute-on-chronic liver failure
Researchers agree on core elements of ACLF development, including chronic liver disease triggers, acute insult, and extrahepatic organ failure. A new three-stage mouse model supports testing of potential therapies, highlighting impaired liver regeneration as a key driver of disease progression.
PCORI awards funding for new patient-centered healthcare research supporting better-informed decision making
The Patient-Centered Outcomes Research Institute (PCORI) has awarded funding for new patient-centered comparative clinical effectiveness research projects. These studies will examine different approaches to care across various health concerns, aiming to generate evidence for patients to make informed choices.
Re-conceptualizing Parkinson’s disease as a lifelong neurobiological trajectory: A framework for prevention
A new review proposes a prevention-focused framework for understanding Parkinson's disease risk, highlighting the role of early-life vulnerability, environmental exposures, and resilience factors. The study suggests that susceptibility to PD may begin earlier in life through interactions between biology and environment.
Study finds three distinct patterns of cognitive decline in Alzheimer’s disease
Researchers found three distinct trajectories of cognitive decline: stable, slow and fast decline. Biomarker data showed that participants who declined faster had higher P-tau217 levels and smaller hippocampi.
New research from the COSMOS trial reveals more than 75% of older adults have used complementary therapies
A new study reveals that over 75% of older adults have used complementary health approaches, including mindfulness, yoga, tai chi, acupuncture, and more. The study highlights the need for healthcare providers to discuss the risks and benefits of these therapies with their patients.
Alliance study shows new promise against locally advanced lung cancer
A study by the Alliance Foundation Trials shows that combining immunotherapy and chemotherapy before surgery can help more patients with locally advanced non-small cell lung cancer undergo complete cancer resection, improving their long-term health. The treatment also led to high rates of lymph node clearance and successful surgical re...
Exercise and cancer research: Ibuprofen is another option to ease chemo-brain
A new study suggests that a low dose of ibuprofen can help alleviate chemo-brain symptoms in cancer patients, but exercise remains the most beneficial intervention. Researchers randomized 86 patients to receive either exercise plus ibuprofen or other treatments and found that exercise significantly improved cognitive function.
First-in-human trial primes immune system to accept donor livers
A first-in-human trial shows that an infusion of immune cells derived from a donor's blood can prime the recipient's immune system to accept a donor liver, potentially reducing lifelong immunosuppression. Eight out of 13 participants achieved complete withdrawal of immunosuppression and remained off for more than three years.
Clinical trial aims to address vaginal complaints after breast cancer diagnosis
A clinical trial aims to evaluate whether laser therapy reduces vaginal dryness caused by breast cancer treatment. The study, REVITALIZE, plans to enroll approximately 250 women with a history of breast cancer who experience moderate to severe vaginal dryness.
Simple procedure relieves painful complications after deep vein thrombosis
A clinical trial has shown that stent placement can effectively treat post-thrombotic syndrome, a common complication of deep vein thrombosis. The study found significant improvements in venous symptoms and overall quality of life for patients who received the procedure.
University of Cincinnati enrolls first patients in clinical trial for prosthetic joint infections
A new clinical trial at the University of Cincinnati is testing a peptide solution to treat prosthetic joint infections after total knee replacement. The trial aims to reduce the need for repeat surgeries and expand the treatment window beyond two weeks.
Understanding pathogenesis of liver cirrhosis for improved clinical management
Researchers compare viral and MASLD cirrhosis pathogenic mechanisms, identifying shared pathways and diagnostic differences. The study aims to establish a framework for prevention, diagnosis, treatment, and monitoring of MASLD cirrhosis.
Nancy L. Lewis, MD, MBS, FACP, named new Chief Scientific Officer for National Comprehensive Cancer Network (NCCN)
Nancy L. Lewis, MD, MBS, FACP, a renowned biomedical researcher and clinical trials expert, has been appointed as the new Chief Scientific Officer of the National Comprehensive Cancer Network (NCCN). She will oversee NCCN's programs to advance clinical trials and improve cancer care outcomes globally.
UH Seidman Cancer Center researchers to test a gut microbiome intervention as part of a cancer therapy regimen
The S2419 BioFront study aims to enroll over 700 patients with advanced renal cell carcinoma and test the safety and efficacy of a CBM588 capsule as part of an immunotherapy-based treatment. The trial seeks to improve outcomes for patients by leveraging the gut microbiome.
Antidepressant unable to prevent chemotherapy-associated nerve damage
A randomized trial found that duloxetine does not prevent painful neuropathy caused by oxaliplatin-based chemotherapy in patients with stage II or III colorectal cancer. The study suggests that duloxetine should only be used for managing existing neuropathy, not prevention.
OYE Therapeutics achieves first patient first dose in 505(b)(2) bridging study
OYE-101, a novel intravenous caffeine formulation, has been developed to accelerate recovery from general anesthesia and deep sedation. The company's lead program is being evaluated in a scientific bridging study to support a 505(b)(2) NDA for OYE-101.
Alliance marks Adolescent and Young Adult Cancer Awareness Week
The Alliance for Clinical Trials in Oncology is enrolling adolescent and young adult cancer patients in various trials, including genetic services and treatment studies. These trials aim to address longstanding gaps in care and improve outcomes for AYAs with cancer.
New study finds interferon therapy to be well-tolerated in compensated hepatitis B cirrhosis
A multicenter analysis of 920 patients with compensated cirrhosis found that interferon therapy was not associated with a higher risk of serious complications compared to standard treatment. Milder side effects were more common and required closer monitoring.
Chinese Medical Journal review illuminates the multifaceted role of LRRK2 in health and disease
The review highlights LRRK2's diverse cellular functions and pathogenic mechanisms in various diseases, including Parkinson's disease and inflammatory disorders. Therapeutic strategies targeting LRRK2, such as kinase inhibitors and emerging approaches like PROTACs and gene therapy, show promise for correcting cellular imbalances and re...
AstraZeneca joins Robert A. Winn Excellence in Clinical Trials Award Program as Funding Partner
The Robert A. Winn Excellence in Clinical Trials Award Program has partnered with AstraZeneca to support five medical students participating in the Winn Clinical Investigator Pathway Program (Winn CIPP). The program provides immersive training, mentorship, and hands-on experience to prepare students for careers in clinical research.
Study illuminates benefits of red blood cell exchange in severe babesiosis
A multicenter study found that red blood cell exchange transfusion significantly improves clinical outcomes for patients hospitalized with severe babesiosis, a potentially life-threatening tick-borne infection. The procedure was associated with substantially lower risk of in-hospital death or readmission.
Mitral valve-in-valve procedure associated with lower risk of death, disabling strokes
A minimally invasive procedure to insert a new valve showed lower one-year event rates for death or disabling stroke compared to traditional repeat mitral valve replacement surgery. The study found that transcatheter mitral valve-in-valve (mVIV) reduced in-hospital deaths, acute kidney injury, and life-threatening bleeding complications.
Minimally invasive valve repair reduces heart failure hospitalizations in patients with severe tricuspid regurgitation
A minimally invasive procedure using a clip to repair the valve significantly reduced heart failure hospitalizations by 40% in patients with severe tricuspid regurgitation. The study, presented at the American College of Cardiology's Annual Scientific Session, showed improved long-term outcomes without crossover between treatment groups.
Older, high-risk patients can safely defer PCI until after TAVR
The PRO-TAVI study found that older, high-risk patients can safely defer percutaneous coronary intervention (PCI) until after transcatheter aortic valve replacement (TAVR), with comparable outcomes between the two groups. Omitting PCI before TAVR did not increase the risk of death, heart attack, stroke, or moderate to severe bleeding.
Direct comparison shows stroke protection devices during TAVR perform alike
The Emboliner device performed comparably to the Sentinel device in protecting against stroke and death in patients undergoing TAVR. The study found that both devices captured similar amounts of debris particles, with the Emboliner capturing three times as many larger particles.
Microaxial flow pump does not improve outcomes for high-risk heart attack patients without cardiogenic shock
A new trial found that using a microaxial flow pump before and during cardiac stenting procedures for high-risk heart attack patients with severe heart attacks did not reduce heart damage. The study, published in the Journal of the American College of Cardiology, also showed increased bleeding complications.
TENS improves pain and fatigue in fibromyalgia
A new study led by University of Iowa Health Care researchers found that TENS reduced movement-evoked pain and fatigue in patients with fibromyalgia, with effects lasting for at least six months. The treatment was also shown to be safe, effective, inexpensive, and readily available.
New study finds common blood pressure drug boosts cancer treatment
A new study found that the common blood pressure medication telmisartan can significantly enhance the cancer-killing activity of olaparib, potentially expanding its use to many more patients. Telmisartan made tumors more vulnerable to PARP inhibitors, even when they lacked specific DNA repair defects.
Largest study of its kind tests hydration strategy for kidney stones
The largest behavioral study on kidney stone prevention tested a hydration program with Bluetooth-enabled smart water bottles and personalized hydration goals. While participants did hydrate more, the increase wasn't large enough to lower symptomatic kidney stone recurrence across the group.
Clinical trial results support use of weekly extended-release buprenorphine for treatment of opioid use disorder during pregnancy
A clinical trial found that weekly injectable extended-release buprenorphine treatment resulted in higher rates of illicit opioid abstinence during pregnancy compared to sublingual buprenorphine. Serious adverse events were also less common in the extended-release group.
New alliance clinical trial aims to improve outcomes in brain tumors
A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...
Timely scan could save lives of A&E patients with blood in urine
A new study found that A&E patients with visible blood in their urine who receive a scan within 48 hours are 2.5% less likely to die within three months. The study also showed that patients with cancer are diagnosed significantly faster when they receive prompt investigation.
Smartphone app can help men last longer in bed
A new smartphone app has been shown to significantly improve sex life and delay ejaculation in men with premature ejaculation. The app, developed by urologists and psychologists, teaches men therapeutic techniques and exercises to manage arousal and control ejaculation.
Can exercise help chemo brain? New research adds promising results
A new study suggests that exercise can improve mental sharpness and reduce cognitive decline in cancer patients undergoing chemotherapy. Researchers found that patients who exercised while on chemotherapy maintained their daily step goals and reported improved mental clarity, while those who did not exercise experienced significant dec...
VR could reduce anxiety for people undergoing medical procedures
A new study suggests that using virtual reality (VR) to explain medical procedures can help patients better understand their treatment and reduce anxiety. The research tested VR as part of the consent process for a procedure to treat kidney stones, with patients reporting improved understanding and reduced anxiety after the experience.
The ISSCR launches new continuing education course on stem cell therapies for Parkinson’s disease
The ISSCR has launched a new continuing education course on stem cell therapies for Parkinson’s disease, addressing the need for clinicians to provide accurate information on emerging treatments. The course features expert faculty and patient perspectives, and is available through a free and paid pathway.
$3.4 million grant to improve weight-management programs
A $3.4 million NIH grant will fund a semi-automated feedback system to support people tracking diet, exercise, and weight in weight-management programs. The system aims to provide personalized feedback to increase tracking and weight loss success.
Research presented at international urology conference in London shows how far prostate cancer screening has come
Research presented at EAU26 confirms that prostate cancer screening leads to a reduction in mortality, but also detects cancers that would otherwise remain undetected. The study's findings suggest that using MRI in prostate cancer screening can reduce overdiagnosis and unnecessary biopsies.
Gene therapy for Duchenne muscular dystrophy: Genethon confirms two-year efficacy in patients treated with its drug candidate GNT0004 at therapeutic dose in the first phase of its clinical trial
Genethon's GNT0004 gene therapy shows long-term efficacy in patients with Duchenne muscular dystrophy, maintaining clinical efficacy and safety at two years. The trial included 72 boys aged 6-10 with retained walking ability, treated with GNT0004 at a therapeutic dose.
Alliance trial aims to improve outcomes for chronic lymphocytic leukemia
The Alliance trial explores the combination of zanubrutinib and sonrotoclax for CLL treatment, aiming to send cancer into remission and allow patients to stop treatment earlier. The study has the potential to be life-changing for patients and their families, reducing the burden of ongoing therapy and improving quality of life.
Severe COVID-19, flu facilitate lung cancer months or years later, new research shows
Severe COVID-19 and influenza infections can prime the lungs for cancer development, according to new research. Vaccination, however, largely prevents these changes, suggesting a reduced risk of lung cancer.
Atamyo Therapeutics presents promising results in the first patients treated with its ATA-200 gene therapy in the clinical trial targeting LGMD-R5 limb-girdle muscular dystrophy
The company's ATA-200 gene therapy has shown safety, pharmacodynamics, and efficacy results in the first patients treated, offering hope for children with LGMD-R5. The therapy delivers a normal copy of the γ-sarcoglycan gene and has been awarded Orphan Drug Designation in the US and Europe.
Alliance for Clinical Trials in Oncology highlights new and open colorectal cancer trials in March
The Alliance for Clinical Trials in Oncology is spotlighting new trials for colorectal cancer in March, focusing on early detection methods and treatments for treatment delays and loss of appetite. The trials aim to improve patient outcomes, with several enrolling patients with newly diagnosed colon or rectal cancer.
New trial seeks to improve sharing of genetic colorectal cancer risks
A new clinical study aims to improve communication between patients and families about genetic risks of colorectal cancer. The trial will compare two methods of sharing genetic test results with close relatives, with the goal of learning which approach helps more family members get necessary genetic testing.
AI-driven chart review accurately identifies potential rare disease trial participants in new study
A new study by Cleveland Clinic and Dyania Health demonstrates the potential of large language models in accurately identifying patients who could benefit from clinical research. The AI system reviewed 1,476 patients and identified 46 as potential matches, resulting in a more diverse patient population.
Natural anti-inflammatory could save lives of sepsis patients
Researchers at Adelaide University have discovered a naturally occurring protein that can protect against sepsis by reducing inflammation. The protein, corticosteroid-binding globulin (CBG), has been shown to reduce relative mortality in an animal model with septic shock by over 70 per cent.
Acoziborole Winthrop, developed by DNDi and Sanofi, receives European Medicines Agency positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
The European Medicines Agency has granted a positive opinion to Acoziborole Winthrop as a single-dose oral treatment for both early- and advanced-stage gambiense sleeping sickness in adults and adolescents. The medicine, co-developed by DNDi and Sanofi, could provide a significant advance over current therapies.
Blood test predicts which bladder cancer patients may safely skip surgery
Researchers found that circulating tumor DNA can predict metastatic risk in patients treated with bladder-sparing treatment for muscle-invasive bladder cancer. The absence of ctDNA predicted favorable outcomes regardless of bladder removal status.
Aspirin not a quick fix for preventing bowel cancer
Daily aspirin use offers no quick or reliable way to prevent bowel cancer in the general population, increasing risk of serious bleeding. However, it may have potential long-term benefits for people at high genetic risk of colorectal cancer.
Gibson Oncology, NIH to begin Phase 2 trials of LMP744 for treatment of first-time recurrent glioblastoma
Approximately 40 cancer patients will receive LMP744 for five consecutive days, with biological analyses conducted on brain tissues before and after treatment. If results are favorable, treatment will continue for 12 cycles to evaluate parameters such as progression-free survival and overall survival.
Barshop Institute to receive up to $38 million from ARPA-H, anchoring UT San Antonio as a national leader in aging and healthy longevity science
The Barshop Institute will conduct the VITAL-H trial, evaluating the repurposing of FDA-approved medications to delay age-related health decline in generally healthy middle-aged adults. The trial aims to preserve everyday abilities during a critical window of midlife aging.